Neuroprotection of agomelatine against cerebral ischemia/reperfusion injury through an antiapoptotic pathway in rat

Chumboatong, Wijitra; Thummayot, Sarinthorn; Govitrapong, Piyarat; Tocharus, Chainarong; Jittiwat, Jinatta; Tocharus, Jiraporn

doi:10.1016/j.neuint.2016.12.011

Cited by 67 publications

(35 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…And they suggested potential implications for the use of melatonin as a therapeutic agent in patients at risk of atherothrombotic events, such as patients with coronary artery disease or systemic hypertension . Other studies also showed that melatonin has emerged as a promising resource for improving neurological recovery from stroke and ischemic brain damage in adults . Torres et al showed that melatonin reduces oxidative stress and improves vascular vasodilator function of small pulmonary arteries in pulmonary hypertensive newborn sheep .…”

Section: Discussionmentioning

confidence: 99%

“…61 Other studies also showed that melatonin has emerged as a promising resource for improving neurological recovery from stroke and ischemic brain damage in adults. [62][63][64][65] Torres et al showed that melatonin reduces oxidative stress and improves vascular vasodilator function of small pulmonary arteries in pulmonary hypertensive newborn sheep. 66 The mechanisms by which melatonin prevents placental malperfusion remains uncertain, but research has focused on melatonin's antioxidative and antiinflammatory effects and its immune modulation.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Melatonin for prevention of placental malperfusion and fetal compromise associated with intrauterine inflammation‐induced oxidative stress in a mouse model

Lee

Shin

et al. 2019

Journal of Pineal Research

View full text Add to dashboard Cite

Melatonin has been shown to reduce oxidative stress and mitigate hypercoagulability. We hypothesized that maternally administered melatonin may reduce placental oxidative stress and hypercoagulability associated with exposure to intrauterine inflammation (IUI) and consequently improve fetoplacental blood flow and fetal sequelae. Mice were randomized to the following groups: control (C), melatonin (M), lipopolysaccharide (LPS; a model of IUI) (L), and LPS with melatonin (ML). The expression of antioxidant mediators in the placenta was significantly decreased, while that of pro‐inflammatory mediators was significantly increased in L compared to C and ML. The systolic/diastolic ratio, resistance index, and pulsatility index in uterine artery (UtA) and umbilical artery (UA) were significantly increased in L compared with other groups when analyzed by Doppler ultrasonography. The expression of antioxidant mediators in the placenta was significantly decreased, while that of pro‐inflammatory mediators was significantly increased in L compared to C and ML. Vascular endothelial damage and thrombi formation, as evidenced by fibrin deposits, were similarly increased in L compared to other groups. Maternal pretreatment with melatonin appears to modulate maternal placental malperfusion, fetal cardiovascular compromise, and fetal neuroinflammation induced by IUI through its antioxidant properties.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Melatonin for prevention of placental malperfusion and fetal compromise associated with intrauterine inflammation‐induced oxidative stress in a mouse model

Lee

Shin

et al. 2019

Journal of Pineal Research

View full text Add to dashboard Cite

show abstract

“…In this sense, a reduced number of melatonin analogues (MCA‐NAT, IIK7, agomelatine, INS48848, INS48862, and INS48852) have been tested for their in vivo ocular hypotensive effect . Additionally, researchers have demonstrated the neuroprotective action of agomelatine, which is a melatonin analogue approved to treat depression . Consequently, it is also necessary to characterize in a more detailed way all the properties of these melatonin analogues to determine their efficacy to treat ocular diseases.…”

Section: Epilogue and Perspectivesmentioning

confidence: 99%

The role and therapeutic potential of melatonin in age‐related ocular diseases

Crooke

Huete-Toral

Colligris

et al. 2017

Journal of Pineal Research

View full text Add to dashboard Cite

The eye is continuously exposed to solar UV radiation and pollutants, making it prone to oxidative attacks. In fact, oxidative damage is a major cause of age-related ocular diseases including cataract, glaucoma, age-related macular degeneration, and diabetic retinopathy. As the nature of lens cells, trabecular meshwork cells, retinal ganglion cells, retinal pigment epithelial cells, and photoreceptors is postmitotic, autophagy plays a critical role in their cellular homeostasis. In age-related ocular diseases, this process is impaired, and thus, oxidative damage becomes irreversible. Other conditions such as low-grade chronic inflammation and angiogenesis also contribute to the development of retinal diseases (glaucoma, age-related macular degeneration and diabetic retinopathy). As melatonin is known to have remarkable qualities such as antioxidant/antinitridergic, mitochondrial protector, autophagy modulator, anti-inflammatory, and anti-angiogenic, it can represent a powerful tool to counteract all these diseases. The present review analyzes the role and therapeutic potential of melatonin in age-related ocular diseases, focusing on nitro-oxidative stress, autophagy, inflammation, and angiogenesis mechanisms.

show abstract

“…Melatonin (MEL) could be a promising neuroprotective agent in traumatic brain injury (TBI). Although MEL's role in the chrono-regulation of major physiological processes (e.g., the sleep wake cycle) is well accepted 7,8 , more recently its therapeutic potential is being explored in acquired brain injury, most notably neonatal hypoxic-ischemic encephalopathy [9][10][11] . MEL has pluripotent antioxidant and anti-inflammatory properties [12][13][14][15] , that are both receptor-mediated (at physiological levels) and non-receptor mediated (especially at supra-physiological levels) [16][17][18][19] .…”

Section: Introductionmentioning

confidence: 99%

Melatonin as a Treatment after Traumatic Brain Injury: A Systematic Review and Meta-Analysis of the Pre-Clinical and Clinical Literature

Barlow

Esser

Veidt

et al. 2019

Journal of Neurotrauma

View full text Add to dashboard Cite

Traumatic brain injury (TBI) is common; however, effective treatments of the secondary brain injury are scarce. Melatonin is a potent, nonselective neuroprotective and anti-inflammatory agent that is showing promising results in neonatal brain injury. The aim of this study was to systematically evaluate the pre-clinical and clinical literature on the effectiveness of melatonin in improving outcome after TBI. Using the systematic review protocol for animal intervention studies (SYRCLE) and Cochrane methodology for clinical studies, a search of English-language articles was performed. Eligible studies were identified and data were extracted. Quality assessment was performed using the SYRCLE risk of bias tool. Meta-analyses were performed using standardized mean differences (SMD). Seventeen studies (15 pre-clinical, 2 clinical) met inclusion criteria. There was heterogeneity in the studies, and all had moderate-to-low risk of bias. Meta-analysis of pre-clinical data revealed an overall positive effect on neurobehavioural outcome with SMD of 1.51 (95% CI: 1.06-1.96). Melatonin treatment had a favorable effect on neurological status, by an SMD of 1.35 (95% CI: 0.83-1.88), and on cognition by an SMD of 1.16 (95% CI: 0.4-1.92). Melatonin decreased the size of the contusion by an SMD of 2.22 (95% CI: 0.8--3.59) and of cerebral edema by an SMD of 1.91 (95% CI: 1.08-2.74). Only two clinical studies were identified. They were of low quality, were used for symptom management, and were of uncertain significance. In conclusion, there is evidence that melatonin treatment after TBI significantly improves both behavioral outcomes and pathological outcomes; however, significant research gaps exist, especially in clinical populations.

show abstract

Neuroprotection of agomelatine against cerebral ischemia/reperfusion injury through an antiapoptotic pathway in rat

Cited by 67 publications

References 25 publications

Melatonin for prevention of placental malperfusion and fetal compromise associated with intrauterine inflammation‐induced oxidative stress in a mouse model

Melatonin for prevention of placental malperfusion and fetal compromise associated with intrauterine inflammation‐induced oxidative stress in a mouse model

The role and therapeutic potential of melatonin in age‐related ocular diseases

Melatonin as a Treatment after Traumatic Brain Injury: A Systematic Review and Meta-Analysis of the Pre-Clinical and Clinical Literature

Contact Info

Product

Resources

About